MedTrace Logo

A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone

NCT06862791 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 377

Last updated 2026-04-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether treatment with AZD9550 when given in combination with AZD6234 as once weekly subcutaneous (SC) injections is superior to placebo or either agent administered as monotherapy for weight loss in participants living with obesity or overweight with at least one weight-related co-morbidity.

Conditions

  • Obesity or Overweight

Interventions

DRUG

AZD9550

IMP injected subcutaneous, once weekly. Unit dose strength as per CSP

DRUG

AZD6234

IMP injected subcutaneous, once weekly. Unit dose strength as per CSP.

DRUG

Placebo comparator

Placebo matching IMP dose injected subcutaneously, once weekly.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-18
Primary Completion
2026-05-25
Completion
2026-05-25
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06862791 on ClinicalTrials.gov